证券之星消息，11月17日电子化学品板块较上一交易日上涨0.67%，思泉新材领涨。当日上证指数报收 于3972.03，下跌0.46%。深证成指报收于13202.0，下跌0.11%。电子化学品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301489 | 思泉新材 | 184.89 | 4.89% | 4.61万 | | 8.49亿 | | 603931 | 格林达 | 30.98 | 3.96% | 17.23万 | | · 5.47亿 | | 002741 | 光华科技 | 23.88 | 3.06% | 66.54万 | | 15.93亿 | | 300285 | 国瓷材料 | 25.21 | 2.86% | 41.74万 | | 10.59亿 | | 688603 | 大唐科技 | 72.94 | 2.73% | 1.34万 | | 9757.56万 | | 300655 | 晶瑞电材 | 15.81 | 2.46% | 77.58万 | | 12. ...

证券代码：688389 证券简称：普门科技 公告编号：2025-077 深圳普门科技股份有限公司 关于参加2025年度深圳辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP，参 与本次互动交流，活动时间为2025年11月20日（周四）14:30-17:00。 届时公司管理层将在线就公司业绩、公司治理、发展战略、经营状况等投资 者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 深圳普门科技股份有限公司董事会 2025年11月12日 1 / 1 为进一步加强与投资者的互动交流，深圳普门科技股份有限公司（以下简称 "公司"）将参加由深圳证监局和中证中小投资者服务中心指导、深圳上市公司 协会与深圳市全景网络有限公司联合举办的"2025年度深圳辖区上市公司投资者 网上集体接待日活动"，现将相关事项公告如下： ...

Group 1 - On November 10, a total of 13 companies were investigated by institutions, with 8 companies being surveyed by funds [1] - The most attention was given to Boying Special Welding, which had 17 participating funds, followed by Jiayi Co., Ltd. and Inno Laser with 9 and 5 funds respectively [1] - Among the surveyed companies, there was 1 from the main board, 5 from the ChiNext, 1 from the Sci-Tech Innovation Board, and 1 from the Beijing Stock Exchange [1] Group 2 - Of the companies surveyed, 7 had a total market capitalization of less than 10 billion yuan, including Canaan Technology, Super Equipment, and Boying Special Welding [1] - In terms of market performance, 4 out of the surveyed stocks increased in the last 5 days, with the highest gains from Kelu Electronics, Inno Laser, and Pumen Technology, showing increases of 5.42%, 5.29%, and 1.44% respectively [1] - Conversely, 4 stocks experienced declines, with Tonghui Electronics, Boying Special Welding, and Jiayi Co., Ltd. showing the largest drops of 7.23%, 4.03%, and 3.94% respectively [1]

证券日报网讯普门科技11月10日在互动平台回答投资者提问时表示，经过多年的发展和积累，普门科技 在研发、市场营销、供应链等方面逐步建立起较强的核心能力，初步具备了高效管理和驾驭多产品线、 多市场的能力。 ...

[Table_Reportdate] 2025年11月05日 [证券分析师： Table_Authors] 赖菲虹 S0630525050001 lfhong@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20251105 重点推荐 财经要闻 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 晨 会 纪 要 [table_summary] ➢ 1.北方华创（002371）：2025Q3业绩高速增长，平台化布局成效卓著——公司简评报告 ➢ 2.预定利率研究值小幅下调至1.90%，预计短期上限水平保持稳定——保险业态观察（十） ➢ 3.众生药业（002317）：业绩稳健增长，研发进展顺利——公司简评报告 ➢ 4.普门科技（688389）：国际业务增长迅速，静待行业政策影响出清——公司简评报告 ➢ 5.常熟银行（601128）：息差压力缓解，非息收入增长强劲——公司简评报告 ➢ ...

2、根据《公司2023年股票期权激励计划（草案）》的相关规定，截至2025年9 月11日，鉴于2023年股票期权激励计划授予激励对象中有6名激励对象已离职，以及 公司2023年股票期权激励计划第一个行权期可行权期限已经届满，154名激励对象持 有的股票期权合计1,937,998份（其中包括6名离职激励对象未行权的股票期权120,000 份）在可行权期限内未行权，拟由公司进行注销。 证券代码：688389 证券简称：普门科技 公告编号：2025-076 深圳普门科技股份有限公司 关于2021年股票期权激励计划首次授予部分股票期权、 2023年股票期权激励计划部分股票期权注销完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于2025年10月27日召开了第 三届董事会第十九次会议和第三届监事会第十八次会议，审议通过了《关于注销 2021年股票期权激励计划首次授予部分股票期权的议案》《关于注销2023年股票期 权激励计划部分股票期权的议案》。前述董事会、监事会审议的注销事项具 ...

Core Viewpoint - Pumen Technology (688389) has experienced a decline in stock price and financial performance, with significant drops in revenue and net profit, while international business shows growth potential in the medical device sector [1][3][4]. Stock Performance - As of October 31, 2025, Pumen Technology's stock closed at 13.81 yuan, down 0.14% from the previous week, with a market cap of 5.917 billion yuan, ranking 61st in the medical device sector [1]. Shareholder Changes - As of September 30, 2025, the number of shareholders decreased to 11,900, a reduction of 500 or 4.05%, while the average shareholding increased to 36,100 shares, with an average market value of 499,300 yuan [2]. Financial Performance - For Q3 2025, Pumen Technology reported a main revenue of 763 million yuan, a year-on-year decrease of 10.96%, and a net profit of 163 million yuan, down 36.66%. The gross profit margin was 63.29% [3]. Research and Development - In the first three quarters of 2025, R&D expenses reached 170 million yuan, accounting for 22.23% of revenue, an increase of 4.10 percentage points year-on-year. The gross margin decreased by 3.82 percentage points [4][5]. International Business Growth - International business revenue for the first three quarters was 294 million yuan, representing 39% of total revenue and a year-on-year increase of 16.41%. The international in vitro diagnostics revenue was 270 million yuan, up 14% [4]. Product Development - The company has made significant advancements in product offerings, including the eCL8600 and eCL8800 series, which have met market expectations since their launch in June. The semiconductor laser hair removal device has received FDA certification, facilitating entry into the North American market [4][5]. Consumer Health Business - The consumer health business, while currently a small revenue contributor, has shown significant growth, focusing on home medical aesthetics and rehabilitation products, with positive market feedback [5].

Core Viewpoint - Pumen Technology, a leading medical device company in China, focuses on in vitro diagnostics and rehabilitation products, leveraging technological innovation and a full industry chain advantage to establish its position in the market [1] Group 1: Business Performance - For Q3 2025, Pumen Technology reported revenue of 763 million yuan, ranking 13th among 39 companies in the industry, with the top company, New Industries, achieving 3.428 billion yuan [2] - The net profit for the same period was 159 million yuan, placing the company 8th in the industry, while the leading company, Ji'an Medical, reported a net profit of 1.588 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Pumen Technology's debt-to-asset ratio was 20.77%, lower than the previous year's 30.95% but still above the industry average of 18.29% [3] - The gross profit margin for the same period was 63.29%, down from 69.89% year-on-year, yet higher than the industry average of 56.20% [3] Group 3: Executive Compensation - Chairman Liu Xiancheng's salary increased to 2.0519 million yuan in 2024, up from 977,600 yuan in 2023, reflecting a rise of 1.0743 million yuan [4] - General Manager Hu Minglong's salary rose to 1.2455 million yuan in 2024 from 1.0897 million yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.05% to 11,900, while the average number of circulating A-shares held per shareholder increased by 4.22% to 36,100 [5] - The top ten circulating shareholders include the "Zhaoshang Core Competitiveness Mixed A" fund, holding 6.2561 million shares, unchanged from the previous period [5] Group 5: Market Outlook - According to Dongfang Securities, Pumen Technology's mid-year report for 2025 indicated a year-on-year decline in revenue and net profit, with domestic business under short-term pressure but international business showing steady growth [5] - Huachuang Securities noted that while the company's mid-year performance declined, Q2 2025 saw a return to growth, with international business performing well despite short-term challenges in the IVD sector [5]

Core Viewpoint - The company, Pumen Technology, reported a decline in revenue and net profit for the first three quarters of 2025, with a focus on improving its product offerings and market competitiveness in the IVD and treatment sectors [2][12]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 763 million yuan, a year-on-year decrease of 10.96% - The net profit attributable to the parent company was 163 million yuan, down 36.66% year-on-year - The net profit after deducting non-recurring gains and losses was 153 million yuan, a decline of 37.18% year-on-year - In Q3 2025, the company reported revenue of 256 million yuan, a decrease of 4.06% year-on-year, and a net profit of 41.46 million yuan, down 51.52% year-on-year [2][12]. R&D and Product Development - The company invested 170 million yuan in R&D for the first three quarters, accounting for 22.23% of revenue, with a year-on-year increase of 9.20% in R&D expenses [2][8]. - The company has established two business units focusing on IVD and treatment & rehabilitation, with ongoing efforts in new product development and upgrades to existing products [8][9]. Market and Product Strategy - The domestic IVD business faced challenges due to industry policies, but the company is seeing growth in its glycated hemoglobin testing products, particularly the H100Plus model, which has been installed in several top-tier hospitals [3][4]. - The company has successfully installed its eCL9000 series and LifoLas systems in multiple hospitals, establishing a comprehensive product matrix to meet various medical institution needs [4]. - International business revenue reached 294 million yuan, accounting for 39% of total revenue, with a year-on-year growth of 16.41% [6]. Future Outlook - The company plans to continue its R&D investments and product international registrations, aiming to enhance product competitiveness and market presence [9]. - Measures to improve gross margins include technological innovation, self-research of key raw materials, and cost control strategies [10].

Core Insights - The Social Security Fund has disclosed its stock holdings as of the end of the third quarter, appearing in the top ten shareholders of 49 stocks on the Sci-Tech Innovation Board, with a total holding of 203 million shares valued at 13.02 billion yuan [1][2]. Holdings Overview - The Social Security Fund initiated positions in 19 new stocks and increased holdings in 11 stocks, while reducing holdings in 11 stocks, with 8 stocks remaining unchanged [1]. - Among the newly added stocks, Pumen Technology, Hangya Technology, and Sanyou Medical had the largest shareholdings [1]. - The stocks with the highest proportion of holdings by the Social Security Fund include Kaili New Materials at 5.80% and Haitai New Light at 4.20% [2]. Stock Performance - The average performance of the Sci-Tech Innovation Board stocks held by the Social Security Fund has seen a decline of 2.05% since October [3]. - The best-performing stock is Western Superconducting, which has increased by 34.00%, while the worst performer is Jiahe Meikang, which has decreased by 20.25% [3]. Financial Performance - Among the stocks held by the Social Security Fund, 30 companies reported year-on-year net profit growth in the first three quarters, with Rongzhi Rixin showing the highest increase of 889.54% [2]. - Other notable companies with significant net profit growth include Sanyou Medical and Shenkong Co., with increases of 623.19% and 158.93%, respectively [2]. Industry Distribution - The holdings of the Social Security Fund are primarily concentrated in the electronics, pharmaceutical and biological, and machinery equipment sectors, with 15, 7, and 7 stocks in these categories, respectively [2].